Stereotaxis (STXS) 2.15 $STXS
Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years
GlobeNewswire - Mon Mar 30, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it has extended the maturity of its revolving credit facility with Silicon Valley Bank (SVB) by three years to March 31, 2018. The amended agreement maintains the existing line capacity of $10 million, which was increased from $3 million in 2014.
SIVB: 128.76 (-1.97), STXS: 2.15 (-0.09)
Florida Hospital First in U.S. to Use Stereotaxis Vdrive(R) Duo(TM) System to Control Multiple Diagnostic Devices
GlobeNewswire - Fri Mar 27, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and the Florida Hospital Cardiovascular Institute in Orlando, Fla., today announced the first use of the Stereotaxis Vdrive Duo(TM) robotic navigation system in the U.S. to control multiple diagnostic devices during a cardiac ablation procedure. Dr. Usman Siddiqui, an electrophysiologist with the Florida Hospital Cardiovascular Institute, performed the procedure in early February.
STXS: 2.15 (-0.09)
Stereotaxis' (STXS) CEO William Mills on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 6:35PM CST
STXS: 2.15 (-0.09)
Stereotaxis reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 3:17PM CST
STXS: 2.15 (-0.09)
Stereotaxis joins the nano cap rally
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 3:08PM CST
STXS: 2.15 (-0.09)
CHU de Saint-Etienne Launches Second Stereotaxis Lab
GlobeNewswire - Wed Feb 18, 3:34PM CST
Stereotaxis, Inc. (Nasdaq:STXS) and Centre Hospitalier Universitaire (CHU) of Saint-Etienne, France, today announced the installation of the hospital's second Niobe(R) remote magnetic navigation system for the treatment of complex arrhythmias through electrophysiology (EP) ablation. To celebrate the launch of the new Stereotaxis lab, the hospital held a grand opening ceremony on February 3. CHU of Saint-Etienne represents the first healthcare provider in Europe to utilize two Niobe systems for clinical procedures.
STXS: 2.15 (-0.09)
Stereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
GlobeNewswire - Wed Feb 18, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2014 fourth quarter and full year ended December 31, 2014 on Wednesday, February 25, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 2.15 (-0.09)
Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures
GlobeNewswire - Tue Jan 13, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) and Princess Grace Hospital of Monaco today announced the results of a recent clinical study conducted in Europe, which represent significant findings in terms of the Stereotaxis remote magnetic navigation platform's success in treating atrial fibrillation (AF).
STXS: 2.15 (-0.09)
Tucson Medical Center and Stereotaxis Bring First Vdrive(R) With V-Loop(TM) System to U.S.
GlobeNewswire - Thu Jan 08, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Tucson Medical Center, Tucson, Arizona's locally governed nonprofit regional hospital since 1944, announced today that they have teamed up to bring the first Stereotaxis Vdrive(R) robotic navigation system with V-Loop(TM) variable loop catheter manipulator to the U.S.
STXS: 2.15 (-0.09)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 327.89 (+0.99), BRID: 8.30 (unch), ASBB: 21.10 (+0.40), WVFC: 11.68 (+0.18), CALI: 2.28 (-0.05), SFST: 17.89 (-0.01), WBB: 17.20 (-0.11), ANTH: 5.20 (+0.31), ANAT: 101.35 (+0.58), BTA: 11.43 (+0.01), FBMS: 16.64 (+0.19), ATHX: 1.29 (-0.03), STXS: 2.15 (-0.09), PZZI: 7.94 (+0.08)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 66.37 (-1.38), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), GM: 35.59 (-0.33), STXS: 2.15 (-0.09)
Stereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System
GlobeNewswire - Tue Jan 06, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a leading provider of innovative technologies for the treatment of cardiac arrhythmias, announced today that more than 75,000 patient cases have been completed with its remote magnetic navigation technology. The Company also announced that it will present the latest enhancements and clinical data for its industry leading robotic platform at the upcoming International AF Symposium, January 8-10, 2015 in Orlando, FL (Booth #816). Now in its 20 year, the annual three-day symposium brings together the world's leading medical scientists and providers to discuss the most recent advances in the field of atrial fibrillation.
STXS: 2.15 (-0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 1.84 (unch), XENT: 25.91 (-0.24), WLL: 35.62 (-1.01), BTE: 19.52 (+0.11), BOTA: 2.41 (+0.08), CNAT: 6.66 (-0.15), WG: 2.61 (-0.15), SN: 13.58 (-0.05), LPI: 14.72 (-0.32), EROC: 2.55 (+0.03), BCLI: 4.14 (+0.02), NDRM: 13.61 (-0.14), SMLR: 3.75 (+0.34), QURE: 26.09 (-0.28), SFY: 2.91 (-0.07), ANTH: 5.20 (+0.31), PLX: 2.23 (+0.01), APRI: 1.61 (-0.13), STXS: 2.15 (-0.09), GST: 3.30 (-0.04)
Stereotaxis (STXS) Stock Soars Today After FDA Clears Vdrive for Market Entry
at The Street - Mon Jan 05, 11:06AM CST
Shares of Stereotaxis (STXS) are up today after announcing that it has received 510(k) clearance by the FDA for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in the U.S.
STXS: 2.15 (-0.09)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST
CERS: 4.79 (+0.20), E: 36.82 (-0.26), SSL: 39.58 (-0.09), CNAT: 6.66 (-0.15), SDRL: 11.39 (-0.26), NBG: 1.23 (+0.06), BCLI: 4.14 (+0.02), URZ: 1.25 (-0.04), PBR: 9.99 (+0.59), ISIS: 66.37 (-1.38), KITE: 60.58 (-0.35), PLX: 2.23 (+0.01), CEMP: 39.02 (+0.23), STXS: 2.15 (-0.09)
Stereotaxis products clear regulatory hurdles
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:11AM CST
STXS: 2.15 (-0.09)
Stereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan
GlobeNewswire - Mon Jan 05, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in the U.S., representing the Company's third Vdrive system product to be cleared for market entry. The Company also announced that it has received regulatory approval of its Odyssey(R) product line by the Japan Pharmaceuticals and Medical Devices Agency, the country's equivalent to the U.S. FDA.
STXS: 2.15 (-0.09)
Insider Trading Alert - CODE, COV And STXS Traded By Insiders
at The Street - Tue Dec 09, 10:37AM CST
Stocks with insider trader activity include CODE, COV and STXS
COV: 106.71 (-1.36), STXS: 2.15 (-0.09), CODE: 38.59 (+0.47)
Stereotaxis' CEO William Mills on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:10PM CST
STXS: 2.15 (-0.09)
Stereotaxis Q3 EPS of -$0.10
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
STXS: 2.15 (-0.09)
Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years
GlobeNewswire - Mon Mar 30, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it has extended the maturity of its revolving credit facility with Silicon Valley Bank (SVB) by three years to March 31, 2018. The amended agreement maintains the existing line capacity of $10 million, which was increased from $3 million in 2014.
SIVB: 128.76 (-1.97), STXS: 2.15 (-0.09)
Florida Hospital First in U.S. to Use Stereotaxis Vdrive(R) Duo(TM) System to Control Multiple Diagnostic Devices
GlobeNewswire - Fri Mar 27, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and the Florida Hospital Cardiovascular Institute in Orlando, Fla., today announced the first use of the Stereotaxis Vdrive Duo(TM) robotic navigation system in the U.S. to control multiple diagnostic devices during a cardiac ablation procedure. Dr. Usman Siddiqui, an electrophysiologist with the Florida Hospital Cardiovascular Institute, performed the procedure in early February.
STXS: 2.15 (-0.09)
Stereotaxis' (STXS) CEO William Mills on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 6:35PM CST
STXS: 2.15 (-0.09)
Stereotaxis reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 3:17PM CST
STXS: 2.15 (-0.09)
Stereotaxis joins the nano cap rally
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 3:08PM CST
STXS: 2.15 (-0.09)
CHU de Saint-Etienne Launches Second Stereotaxis Lab
GlobeNewswire - Wed Feb 18, 3:34PM CST
Stereotaxis, Inc. (Nasdaq:STXS) and Centre Hospitalier Universitaire (CHU) of Saint-Etienne, France, today announced the installation of the hospital's second Niobe(R) remote magnetic navigation system for the treatment of complex arrhythmias through electrophysiology (EP) ablation. To celebrate the launch of the new Stereotaxis lab, the hospital held a grand opening ceremony on February 3. CHU of Saint-Etienne represents the first healthcare provider in Europe to utilize two Niobe systems for clinical procedures.
STXS: 2.15 (-0.09)
Stereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
GlobeNewswire - Wed Feb 18, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2014 fourth quarter and full year ended December 31, 2014 on Wednesday, February 25, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 2.15 (-0.09)
Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures
GlobeNewswire - Tue Jan 13, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) and Princess Grace Hospital of Monaco today announced the results of a recent clinical study conducted in Europe, which represent significant findings in terms of the Stereotaxis remote magnetic navigation platform's success in treating atrial fibrillation (AF).
STXS: 2.15 (-0.09)
Tucson Medical Center and Stereotaxis Bring First Vdrive(R) With V-Loop(TM) System to U.S.
GlobeNewswire - Thu Jan 08, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Tucson Medical Center, Tucson, Arizona's locally governed nonprofit regional hospital since 1944, announced today that they have teamed up to bring the first Stereotaxis Vdrive(R) robotic navigation system with V-Loop(TM) variable loop catheter manipulator to the U.S.
STXS: 2.15 (-0.09)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 327.89 (+0.99), BRID: 8.30 (unch), ASBB: 21.10 (+0.40), WVFC: 11.68 (+0.18), CALI: 2.28 (-0.05), SFST: 17.89 (-0.01), WBB: 17.20 (-0.11), ANTH: 5.20 (+0.31), ANAT: 101.35 (+0.58), BTA: 11.43 (+0.01), FBMS: 16.64 (+0.19), ATHX: 1.29 (-0.03), STXS: 2.15 (-0.09), PZZI: 7.94 (+0.08)
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors
PR Newswire - Tue Jan 06, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Stereotaxis (NASDAQ: STXS), Kite Pharma (NASDAQ: KITE), ISIS Pharma (NASDAQ: ISIS), Merck (NYSE: MRK), and General Motors (NYSE: GM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ISIS: 66.37 (-1.38), KITE: 60.58 (-0.35), MRK: 57.60 (+0.09), GM: 35.59 (-0.33), STXS: 2.15 (-0.09)
Stereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System
GlobeNewswire - Tue Jan 06, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS), a leading provider of innovative technologies for the treatment of cardiac arrhythmias, announced today that more than 75,000 patient cases have been completed with its remote magnetic navigation technology. The Company also announced that it will present the latest enhancements and clinical data for its industry leading robotic platform at the upcoming International AF Symposium, January 8-10, 2015 in Orlando, FL (Booth #816). Now in its 20 year, the annual three-day symposium brings together the world's leading medical scientists and providers to discuss the most recent advances in the field of atrial fibrillation.
STXS: 2.15 (-0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 1.84 (unch), XENT: 25.91 (-0.24), WLL: 35.62 (-1.01), BTE: 19.52 (+0.11), BOTA: 2.41 (+0.08), CNAT: 6.66 (-0.15), WG: 2.61 (-0.15), SN: 13.58 (-0.05), LPI: 14.72 (-0.32), EROC: 2.55 (+0.03), BCLI: 4.14 (+0.02), NDRM: 13.61 (-0.14), SMLR: 3.75 (+0.34), QURE: 26.09 (-0.28), SFY: 2.91 (-0.07), ANTH: 5.20 (+0.31), PLX: 2.23 (+0.01), APRI: 1.61 (-0.13), STXS: 2.15 (-0.09), GST: 3.30 (-0.04)
Stereotaxis (STXS) Stock Soars Today After FDA Clears Vdrive for Market Entry
at The Street - Mon Jan 05, 11:06AM CST
Shares of Stereotaxis (STXS) are up today after announcing that it has received 510(k) clearance by the FDA for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in the U.S.
STXS: 2.15 (-0.09)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST
CERS: 4.79 (+0.20), E: 36.82 (-0.26), SSL: 39.58 (-0.09), CNAT: 6.66 (-0.15), SDRL: 11.39 (-0.26), NBG: 1.23 (+0.06), BCLI: 4.14 (+0.02), URZ: 1.25 (-0.04), PBR: 9.99 (+0.59), ISIS: 66.37 (-1.38), KITE: 60.58 (-0.35), PLX: 2.23 (+0.01), CEMP: 39.02 (+0.23), STXS: 2.15 (-0.09)
Stereotaxis products clear regulatory hurdles
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:11AM CST
STXS: 2.15 (-0.09)
Stereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan
GlobeNewswire - Mon Jan 05, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in the U.S., representing the Company's third Vdrive system product to be cleared for market entry. The Company also announced that it has received regulatory approval of its Odyssey(R) product line by the Japan Pharmaceuticals and Medical Devices Agency, the country's equivalent to the U.S. FDA.
STXS: 2.15 (-0.09)
Insider Trading Alert - CODE, COV And STXS Traded By Insiders
at The Street - Tue Dec 09, 10:37AM CST
Stocks with insider trader activity include CODE, COV and STXS
COV: 106.71 (-1.36), STXS: 2.15 (-0.09), CODE: 38.59 (+0.47)
Stereotaxis' CEO William Mills on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:10PM CST
STXS: 2.15 (-0.09)
Stereotaxis Q3 EPS of -$0.10
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:42PM CST
STXS: 2.15 (-0.09)
